Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33504
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurton, Alexandra-
dc.contributor.authorForsyth, Cecily-
dc.contributor.authorRoss, David M-
dc.contributor.authorGrigg, Andrew P-
dc.date2023-
dc.date.accessioned2023-08-16T05:31:25Z-
dc.date.available2023-08-16T05:31:25Z-
dc.date.issued2023-12-
dc.identifier.citationLeukemia & Lymphoma 2023-12; 64(12)en_US
dc.identifier.issn1029-2403-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33504-
dc.description.abstractDespite the recent publication of calreticulin (CALR)-mutated essential thrombocythemia (ET) management guidelines by the European Leukemia Net (ELN), there remains a paucity of data regarding the optimal way to manage this condition. To determine practice around Australia, we constructed a survey asking investigation and treatment questions in a hypothetical case of a young woman with CALR-mutated ET and subsequent progression to myelofibrosis. 51 of 88 hematologists replied. The responses demonstrated significant heterogeneity in specific issues such as the use of aspirin, when to initiate cytoreduction, the preferred type of cytoreduction, and platelet targets. These observations support the ELN acknowledgment that a strong evidence base for many management recommendations is lacking in this disease, and that substantial further research is needed.en_US
dc.language.isoeng-
dc.subjectCalreticulinen_US
dc.subjectmyeloproliferative neoplasmen_US
dc.subjectnational surveyen_US
dc.titleSignificant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleLeukemia & Lymphomaen_US
dc.identifier.affiliationClinical Haematologyen_US
dc.identifier.affiliationCentral Coast Haematology, North Gosford, Australia.en_US
dc.identifier.affiliationDepartment of Clinical Haematology and Bone Marrow Transplantation, Royal Adelaide Hospital, Adelaide, Australia.;Department of Haematology, Flinders Medical Centre, Adelaide, Australia.en_US
dc.identifier.doi10.1080/10428194.2023.2242992en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-4509-2810en_US
dc.identifier.orcid0000-0001-7171-2935en_US
dc.identifier.pubmedid37574855-
dc.description.startpage1-
dc.description.endpage8-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

54
checked on Feb 20, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.